Seattle, WA 98195
United States
University of Washington
Non small cell lung cancer, Stage IV NSCLC, FDG PET CT, Chemoimmunotherapy, pembrolizumab, Liver SUVmax, Cytokines, T cell receptor diversity, Treatment response prediction, Overall survival, Progression free survival, Imaging biomarkers, Circulating immune biomarkers